A detailed history of Eco R1 Capital, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Eco R1 Capital, LLC holds 11,890,843 shares of APLS stock, worth $311 Million. This represents 14.88% of its overall portfolio holdings.

Number of Shares
11,890,843
Previous 11,607,425 2.44%
Holding current value
$311 Million
Previous $445 Million 22.98%
% of portfolio
14.88%
Previous 15.74%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$28.84 - $41.15 $8.17 Million - $11.7 Million
283,418 Added 2.44%
11,890,843 $343 Million
Q2 2024

Aug 14, 2024

BUY
$38.07 - $59.71 $9.52 Million - $14.9 Million
250,000 Added 2.2%
11,607,425 $445 Million
Q1 2024

May 15, 2024

BUY
$55.39 - $72.47 $10.2 Million - $13.4 Million
184,357 Added 1.65%
11,357,425 $668 Million
Q4 2023

Feb 14, 2024

BUY
$37.14 - $64.82 $10.1 Million - $17.7 Million
273,209 Added 2.51%
11,173,068 $669 Million
Q3 2023

Nov 14, 2023

BUY
$23.65 - $89.22 $129 Million - $486 Million
5,448,212 Added 99.94%
10,899,859 $415 Million
Q1 2023

May 15, 2023

BUY
$46.59 - $66.96 $12.5 Million - $18 Million
268,216 Added 5.17%
5,451,647 $360 Million
Q1 2022

May 16, 2022

BUY
$35.46 - $54.12 $40.8 Million - $62.2 Million
1,149,549 Added 28.5%
5,183,431 $263 Million
Q4 2021

Feb 14, 2022

BUY
$30.74 - $49.16 $124 Million - $198 Million
4,033,882 New
4,033,882 $191 Million
Q2 2018

Aug 14, 2018

SELL
$19.63 - $30.0 $20.7 Million - $31.7 Million
-1,056,348 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$14.01 - $26.02 $1.24 Million - $2.3 Million
-88,210 Reduced 7.71%
1,056,348 $23.4 Million
Q4 2017

Feb 14, 2018

BUY
$12.71 - $21.7 $14.5 Million - $24.8 Million
1,144,558
1,144,558 $24.8 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2.88B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Eco R1 Capital, LLC Portfolio

Follow Eco R1 Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eco R1 Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eco R1 Capital, LLC with notifications on news.